PHARMA-BIO SERV, INC. Unrealized Gain (Loss) on Derivatives
PHARMA-BIO SERV, INC. (PBSV) reported Unrealized Gain (Loss) on Derivatives of $126.15 thousand for the 3-month period ending 2023-01-31, per its 10-Q filed 2023-03-17.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2023-03-17
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for the quarter ending 2023-01-31 was $126.15K.
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for the quarter ending 2022-10-31 was $209.53K.
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for the quarter ending 2022-07-31 was -$103.36K, a 2075.48% decline year-over-year.
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for the quarter ending 2022-01-31 was -$25.49K.
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for fiscal 2022 was $29.54K.
- PHARMA-BIO SERV, INC. unrealized gain (loss) on derivatives for fiscal 2021 was -$16.20K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|
| 2023-01-31 | $126.15K 10-Q · filed 2023-03-17 | $335.69K derived: sum of 2 quarters · filed 2023-03-17 | $232.33K derived: sum of 3 quarters · filed 2023-03-17 | |
| 2022-10-31 | $209.53K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-30 | $106.18K derived: sum of 2 quarters · filed 2023-01-30 | $29.54K 10-K · filed 2023-01-30 | |
| 2022-07-31 | -$103.36K 10-Q · filed 2022-09-14 | -$179.99K 10-Q · filed 2022-09-14 | ||
| 2022-01-31 | -$25.49K 10-Q · filed 2023-03-17 | -$75.42K derived: sum of 2 quarters · filed 2023-03-17 | -$70.18K derived: sum of 3 quarters · filed 2023-03-17 | |
| 2021-10-31 | -$49.92K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-30 | -$44.69K derived: sum of 2 quarters · filed 2023-01-30 | -$16.20K 10-K · filed 2023-01-30 | |
| 2021-07-31 | $5.23K 10-Q · filed 2022-09-14 | $33.72K 10-Q · filed 2022-09-14 |